Methamphetamine Dependence Clinical Trial
Official title:
Methamphetamine-Quetiapine Interaction in Humans: A Pilot Study
This study will test the ability of a medicine (Quetiapine) that is used to treat schizophrenia or bipolar disorder to reduce the effects of methamphetamine that make it difficult for users to stop using it. This study will test the ability of a medicine that is used to treat schizophrenia or bipolar disorder to reduce the effects of methamphetamine that make it difficult for users to stop using it. The investigator thinks quetiapine will lessen the effects of methamphetamine.
The specific goal of this project is to examine whether quetiapine will alter the behavioral
effects of methamphetamine without producing major cardiovascular changes or toxic effects
under controlled laboratory conditions. This goal will be accomplished using a
methamphetamine challenge procedure in which quetiapine will be given orally prior to
intravenous (iv) methamphetamine administration. This will allow rapid and systematic
evaluation of the therapeutic potential of this medication.
Results of this drug-interaction study will help determine further investigations of the
clinical efficacy of this and other dopamine-active agents. We hypothesize that quetiapine
will reduce the self-reported, performance and cardiovascular effects of methamphetamine.
;
Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment
| Status | Clinical Trial | Phase | |
|---|---|---|---|
| Terminated |
NCT01813656 -
An Study of Aripiprazole in the Treatment of Methamphetamine Dependence
|
Phase 4 | |
| Completed |
NCT00984360 -
Study of Naltrexone for Methamphetamine Addiction
|
Phase 2 | |
| Completed |
NCT01685463 -
Transcranial Magnetic Stimulation Used to Both Measure Cortical Excitability and Explore Methamphetamine Cue Craving
|
N/A | |
| Completed |
NCT00569374 -
Safety and Tolerability of Modafinil for Methamphetamine Dependence
|
Phase 2 | |
| Completed |
NCT01967381 -
Targeting GABA and Opioid Systems for a Pharmacotherapy for Methamphetamine Abuse
|
Early Phase 1 | |
| Completed |
NCT01354470 -
A Randomized, Placebo-Controlled Trial of Modafinil for Methamphetamine Dependence
|
Phase 2 | |
| Active, not recruiting |
NCT01044238 -
Methylphenidate to Treat Methamphetamine Dependence
|
Phase 2 | |
| Completed |
NCT01215929 -
Studying Amphetamine Withdrawal in Humans
|
Phase 2 | |
| Terminated |
NCT01019707 -
Safety Assessment of Atomoxetine With MA IV Administration
|
Phase 1 | |
| Completed |
NCT00227123 -
A Randomized Control Trial Comparing Quetiapine to Risperidone in Bipolar Disorder With Stimulant Dependence
|
N/A | |
| Recruiting |
NCT02568878 -
Creatine for Depressed Male and Female Methamphetamine Users
|
Phase 3 | |
| Completed |
NCT01007539 -
Efficacy and Safety of CDP-choline in Patients With Methamphetamine Dependence
|
Phase 3 | |
| Completed |
NCT01011829 -
Varenicline vs Placebo for the Treatment of Methamphetamine Dependence
|
Phase 2 | |
| Completed |
NCT01062451 -
An ACE Inhibitor (Perindopril) or an Angiotensin Receptor Blocker (Candesartan) as a Treatment for Methamphetamine Dependence
|
Phase 1 | |
| Completed |
NCT00687713 -
Phase 2, Double-Blind, Placebo-Controlled Trial of Bupropion for Methamphetamine Dependence
|
Phase 2 | |
| Completed |
NCT01063205 -
NAC as a Potential Treatment for Methamphetamine Dependence
|
Phase 1 | |
| Completed |
NCT02058966 -
Pilot Study of Entacapone for Methamphetamine Abuse
|
Early Phase 1 | |
| Completed |
NCT00332605 -
N-Acetyl Cysteine Plus Naltrexone in Methamphetamine Dependence
|
Phase 2 | |
| Completed |
NCT01860807 -
Trial of Ibudilast for Methamphetamine Dependence
|
Phase 2 | |
| Terminated |
NCT01813643 -
A Comparison of Risperidone and Aripiprazole for Treatment of Patirnts With Methamphetamine-Associated Psychosis
|
Phase 4 |